The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC).
Gerald Schmid-Bindert
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Vittorio Gebbia
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Edurne Arriola
No relevant relationships to disclose
Diego Marquez-Medina
Consultant or Advisory Role - Lilly
Konstantinos N. Syrigos
No relevant relationships to disclose
Bonne Biesma
No relevant relationships to disclose
Monika Iris Leschinger
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Carla M. Visseren Grul
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Bente Frimodt-Moller
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Veronique Ripoche
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Scott Myrand
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Tuan Nguyen
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Annamaria Zimmermann
Employment or Leadership Position - Lilly
Stock Ownership - Lilly (B)
Wolfgang Schuette
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Research Funding - Lilly